Experimental antibody enables lasting platelet stability in autoimmune bleeding condition

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding,…

Continue Reading

News Source: medicalxpress.com